A compound with therapeutic potential
OUR FOCUS is on PN6047, a novel potent, selective and biased signalling delta-opioid receptor agonist, which is predicted to reduce common symptoms of chronic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.
In various pre-clinical studies, PN6047 has shown high selectivity and potency, and very convincing efficacy in reducing neuropathic pain without any signs of the unwanted side effects of traditional opioids such as respiratory depression, abuse potential and the development of tolerance.
PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans.
PN6047 has fully drug-able properties and characteristics enabling the production of a commercial solid dosage form.
